BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » Liraglutide compromises pancreatic beta cell function in a humanized mouse model

Liraglutide compromises pancreatic beta cell function in a humanized mouse model

Liraglutide compromises pancreatic beta cell function in a humanized mouse model

On the web-site of Karolinska Institutet, there is a recent post regarding a new publication of high impact:
“Long-term use of liraglutide, a substance that helps to lower blood sugar levels in patients with type 2 diabetes, can have a deteriorating effect on insulin-producing beta cells, leading to an increase in blood sugar levels. This according to a study on mice implanted with human insulin-producing cells conducted by a team of scientists from Karolinska Institutet, and the University of Miami, USA. The researchers flag the possible consequences of this popular form of therapy in Cell Metabolism.”

Read more:

1.   Press release from Karolinska Institutet:  Type 2 diabetes drug can exhaust insulin-producing cells. Fri, feb 12, 2016 08:00 CET

2.   Från Karolinska Institutet (in Swedish):  Läkemedel mot typ 2-diabetes kan trötta ut insulinproducerande celler. 2016-02-12.

3.   Liraglutide compromises pancreatic beta cell function in a humanized mouse model. Midhat H. Abdulreda, Rayner Rodriguez-Diaz, Alejandro Caicedo, Per-Olof Berggren. Cell Metabolism 23, 1-6, March 8, 2016, doi.org/10.1016/j.cmet.2016.01.009. Online February 11, 2016.

 

February 22, 2016 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications May 13, 2026
  • Framsteg för stamcellsterapi vid typ 1-diabetes
    Framsteg för stamcellsterapi vid typ 1-diabetes May 13, 2026
  • Western diet can cause permanent pancreatic damage, new study finds
    Western diet can cause permanent pancreatic damage, new study finds June 13, 2025
  • Årsstämma 26 juni 2025
    Årsstämma 26 juni 2025 June 10, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved